Our goal is to commercialize medical products that combine therapeutic and diagnostic capabilities, utilizing our smart SINNAIS™ implantable pump to deliver drugs locally, incorporating metronomic and biofeedback capabilities to provide personalized medicine and virtual physician services to afect better outcomes.

Latest Investor Presentation

Latest Clinical Presentation





Cognos validation study of its SINNAIS™ technology successfully completed.

Read   Download  

Independent audit for valuation and market readiness finalized.

Read   Download  

Increase demand for better drug delivery a priority for pharma- based cancer therapeutics.

Read   Download  

Animal study of MTX using SINAAIS™ pump is completed.

Read   Download  

Cognos THX Second Quarter 2023 Financial Results

  Date: 06/15/2023
 Time: 3:00PM PST
 Location: LIVE Webinar

Second Quarter 2023 Financial Results & Operational Highlights    

2023 Annual Meeting of Stockholders

  Date: 03/01/2023
 Time: 12:00PM PST
 Location: LIVE Webinar

2023 Annual Stockholder Meeting Report    

SINNAISTMTechnology Overview with Dr. Thomas Chen

  Date: 01/20/2023
 Time: 3:00PM PST
 Location: LIVE Webinar

SINNAISTMTechnology Overview Video    

Cognos THX Fourth Quarter 2022 Financial Results

  Date: 01/15/2023
 Time: 3:00PM PST
 Location: LIVE Webinar

Cognos THX Fourth Quarter 2022 Financial Result Highlights    

SEC Filings

Form Description Date Format
S-4 Registration of material information related to the Cognos/Nocturne merger 08/16/2023 HTML Icon HTML PDF Icon PDF
S-1 Initial registration form for new securities offering. 03/01/2023 HTML Icon HTML PDF Icon PDF
10-Q Quarterly report which provides a continuing view of a company’s financial position. 04/15/2023 HTML Icon HTML PDF Icon PDF
$10.30 USD
Change +$0.24(3.37%)
Open $7.15
Volume 6.1M
52–Week Range $5.61 – $42.65
Day’s Range $10.30 – $10.48
Market Cap $695.8M
Cognos Dynamic Stock Feed

Governance Documents

Investor Update

If you would like to receive updates and investor notifications from Cognos Therapeutics, including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more, please provide us your email contact information.

Investor Questions

Shareholders seeking information can contact investor relations at (XXX) XXX-XXXX or email us at For all other inquiries please call (xxx) xxx-xxxx or email us at